MiNK Therapeutics Inc. (NASDAQ: INKT) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT MINK THERAPEUTICS INC.

MiNK Therapeutics Inc. (NASDAQ: INKT)
Listen to this Section


$11.82
-0.2940 ( -2.43% ) 6.4K

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

Clinical Trial Pipeline Stages


Drug Name Stage
AgenT-797 + botensilimab/balstilimabDetailsGastroesophageal adenocarcinomas, Gastric cancer Phase 2
AgenT-797DetailsVirus-Induced Acute Respiratory Disease Syndrome Phase 1/2
AgenT-797 +/- pembrolizumab/nivolumabDetailsCOVID-19, Acute respiratory distress syndrome, Solid tumor/s, Gastric cancer, Testicular cancer, Cancer, Non-small cell lung carcinoma Phase 1
AgenT-797DetailsGraft-versus-host disease , Immune Disorders Phase 1

Market Data


Open $11.82
Previous Close $12.11
Volume 6.4K
Market Cap $60.33M
Day Range $11.77 - $12.36
52 Week Range $6.80 - $76.00
Shares Outstanding 4.98M
Change % -2.43%
Net Change ▼ -0.2940
Insider Ownership -0.02%
Exchange NASDAQ
SectorHealthcare
IndustryMedicinal Chemicals and Botanical Products
IPO Year2021
CountryUnited States
UnderwriterEvercore ISI, William Blair, B. Riley Securities, Baird, more

Insider Ownership Transactions

Total Amount Purchased: -714,279.00

Date Type Amount Purchased Purchaser
2023-12-05 Sale -17068.00 Ryan Barbara
2023-12-05 Sale -17188.00 Corvese Brian
2023-12-05 Sale -14424.00 WIINBERG ULF
2023-12-05 Sale -14784.00 Behner Peter

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 56 Nov 14, 2025
s-3 Registration statements 18 Nov 07, 2025
4/a Other 1 Oct 03, 2025
8-k 8K-related 11 Sep 29, 2025
4 Insider transactions 1 Sep 11, 2025
4 Insider transactions 1 Sep 11, 2025
4 Insider transactions 1 Sep 11, 2025
4 Insider transactions 1 Sep 11, 2025
4 Insider transactions 1 Sep 11, 2025
4 Insider transactions 1 Sep 11, 2025

Latest News